echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine: "Bringing in" is more open and "Going out" is not slack

    Hengrui Medicine: "Bringing in" is more open and "Going out" is not slack

    • Last Update: 2021-12-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 21, Hengrui Medicine issued an announcement to reach a cooperation with CStone Pharmaceuticals to introduce anti-CTLA-4 monoclonal antibody CS1002


    This is the fourth BD move made public by Hengrui Medicine since the second half of this year


    Start BD acceleration, one external cooperation every month

    Start BD acceleration, one external cooperation every month

    Since the beginning of this year, Hengrui Pharmaceutical's foreign cooperation projects have increased significantly


    In late August, Hengrui reached a cooperation with Dalian Wanchun, a subsidiary of Wanchun Pharmaceutical, to invest 100 million yuan in equity in Dalian Wanchun, and paid a total of not more than 1.


    At the end of the same month, Hengrui signed a contract with Beijing Tianguangshi Biotechnology Co.


    In mid-September, Hengrui and Qiyu Biotech reached a strategic cooperation agreement to carry out clinical trials of Hengrui Medicine Apatinib combined with Qiyu BioQ-1802 (claudin 18.


    In addition to this cooperation with CStone Pharmaceuticals, in just 4 months, Hengrui has reached cooperation with 4 counterparts, involving a total amount of nearly 3 billion yuan


    “In fact, Hengrui has been closely monitoring the progress of external innovation and actively introducing high-quality products.


    Cooperation is more open, innovation and internationalization are not slack

    Cooperation is more open, innovation and internationalization are not slack

    Hengrui's recent open attitude is not only reflected in the frequent BD actions, but also in the exchanges and interactions with external parties including investors


    On October 15, Hengrui Pharmaceuticals held its first R&D day since its listing in Shanghai.


    On this R&D day, Hengrui executives communicated with investors in a very candid manner


    From the recent frequent cooperation projects, Hengrui's words are true


    In the first three quarters of this year, Hengrui Pharmaceutical's accumulated R&D investment has reached 4.


    In addition to the "walking on two legs" in product layout, Hengrui also "consolidates both internally and externally" in market development-consolidating the domestic market and opening up the international market


    Regardless of whether it is self-research + BD, or domestic + international, Hengrui's "walking on two legs" strategy seems to be getting better


    Actively embrace changes and accumulate momentum for steady development

    Actively embrace changes and accumulate momentum for steady development

    In the commercial field, integrating resources to achieve win-win cooperation is a rational choice


    A little in-depth study reveals that Hengrui's recent external cooperations are basically typical projects that "make up for shortcomings" and "strong advantages"
    .
    The anti-CTLA-4 monoclonal antibody CS1002 introduced from CStone Pharmaceuticals is a product that Hengrui has not deployed itself.
    It can form an important supplement to the existing solid tumor product pipeline and also has greater potential for combination medication; the introduction of Tianguangshi Biotechnology The third-generation anti-CD20 monoclonal antibody MIL62 can be used in combination with Hengrui's various hematoma and kidney disease products to complement each other
    .
    The prenabulin imported from Dalian Wanchun is a non-G-CSF drug, and it can be used in combination with Hengrui's existing long-acting G-CSF innovative drug thiopefilgrastim (trade name Aido), which can significantly reduce The incidence of severe CIN, the combination of the advantages of the two will produce greater clinical value; the cooperation with Qiyu Bio will directly focus on its own product apatinib mesylate (trade name Aitan) and the other party's Q- The clinical research of 1802 (claudin 18.
    2/PD-L1 double antibody) in the treatment of advanced gastric cancer can consolidate Hengrui's dominant position in the field of gastric cancer
    .

    Go alone fast, and go far
    .
    Achieving the effect of 1+1>2 through cooperation is an excellent solution for all parties
    .
    With the rapid development and rapid changes of the pharmaceutical innovation industry, Hengrui, who has always been good at grasping trends and insights into the wind, has made his own choices with actions
    .

    Throughout the history of Hengrui's development, we have made the right choice at almost every important juncture, and finally achieved the status of "the first brother of innovative medicine" and "the big white horse of A-share medicine"
    .
    In the face of the new situation, Hengrui strengthens the strategy of "walking on two legs", actively embraces and adapts to changes, or can further accumulate momentum for steady development
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.